High-intensity interval training

As Longevity Investors Conference gets underway,

Longevity.

A study published in

New research highlights the potential of a prote

Startup pet longevity company focused on cats cl

After scrapping initial SPAC deal, Longevity Bio

Natural beauty is increasingly recognized as a v

Are you looking to boost your intake of dihydroq

Longevity.

Aspen Neuroscience announced completion of dosing

A recent study published in

GC Therapeutics’ plug-and-play stem cell progr

Personality changes throughout life can impact m

Global industry leaders converge in Singapore to

VO2 max, or maximal oxygen uptake, is the ultima

Longevity.

As the International Longevity Summit approaches

A new study reveals that baking soda, also known

Supersets are gaining attention as a time-effici

Imagine noticing subtle changes in your memory o

Longevity.

Phase 2 study data indicates ‘dose-dependent i

Company aims to inhibit SARM1 enzyme to prevent

A recent study published in

A new study highlights how three key blood marke

Have you ever questioned whether even a small di

Longevity.

Designed to protect key retinal cells, company’s Fas inhibitor drugs aim to prevent vision loss in a range of conditions. With the world buzzing about Neuralink’s latest project to restore sight to the blind, others take the view that prevention is better than cure. To that end, US biopharma ONL Therapeutics has completed an oversubscribed $65 million Series D financing round to advance the clinical development of its novel therapeutics aimed at protecting retinal cells. ONL’s approach is focused on inhibiting Fas-mediated cell death, a critical mechanism in many ophthalmic diseases. Fas signaling plays a dual role in activating cell death and regulating immune responses, which can further damage retinal cells. The company’s lead compound, ONL1204, is a first-in-class small molecule Fas inhibitor, designed to protect key retinal cells, including photoreceptors, from Fas-induced cell death, a primary cause of vision loss in a range of conditions. By targeting Fas signaling, ONL aims to address both the direct and inflammatory pathways leading to cell death, potentially offering a broad therapeutic benefit across a range of retinal diseases. The funding will be used to initiate a global Phase 2 study in patients suffering from geographic atrophy (GA) linked to dry age-related macular degeneration (AMD).…

Collaboration aims to empower health practitione

TVM Capital Healthcare has announced a strategic

Probiotics are often viewed as the solution to v

A recent study highlights that the “pregnancy

Coya Therapeutics is pioneering multi-pathway th

Elon Musk claims that experimental ‘Blindsight

Achieving glowing skin is a goal for many, and c

Longevity.

A new study published in

Boosting cellular regeneration, reducing inflamm

Different diets have been linked to promoting he

Finding purpose and balance often feels elusive

Chai Discovery emerges with $30m in funding and

Can a simple drink help you shed those stubborn

Longevity.

Zurich-based venture capital firm Ayun has launch

A new study considers epigenetic aging from a si

A recent study published in